Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
Тhe Farmak delegation took part in the last conference and meeting of the ORBIS project in the city of Poznan, Poland. The project lasted 5 years as part of the…